Author:
Puig L.,Carretero G.,Daudén E.,Ferrándiz C.,Marrón S.E.,Martorell A.,Pérez-Suárez B.,Rodriguez-Cerdeira C.,Ruiz-Villaverde R.,Sánchez-Carazo J.L.,Velasco M.
Subject
Dermatology,Histology,Pathology and Forensic Medicine
Reference18 articles.
1. Inflectra Assessment report [consultado 25 Ene 2015]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf
2. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation;Scott;J Clin Pharmacol,2015
3. Biosimilars: In support of extrapolation of indications;Ebbers;J Crohns Colitis,2014
4. The challenge of indication extrapolation for infliximab biosimilars;Feagan;Biologicals,2014
5. SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper;Fiorino;Autoimmun Rev,2014
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献